Scalper1 News
Earnings reports from specialty drugmakers continued to roll in Thursday, as two leading stocks stumbled in the early going on the stock market today. Danish diabetes giant Novo Nordisk (NVO) reported Q2 profit of 2.66 kroner (42 cents) a share, up 7% from the year-earlier quarter and beating analysts’ consensus of 2.59. Sales of 21.6 billion kroner ($3.4 billion), however, were a bit shy of estimates, and up just 1% from the prior year. Novo Scalper1 News
Scalper1 News